PILLETF / FundDirexion Daily Pharmaceutical & Medical Bull 3X Shares
Verdicts genuinely change. Free email alert the moment PILL's does — no target price to set, unlike a price alert.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF · Direxion Shares ETF Trust
73 holdings · as of 2026-07-31 (3.3 months ago) The fund may have traded since. SEC Form N-PORT is filed quarterly and lags the period it covers, so these are the most recent holdings on file, not the fund’s holdings today.
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 134% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT At least 25.76% of portfolio weight is in non-compliant holdings — already over the 5% threshold, so the verdict is settled whatever the unmatched 92% turns out to be. Matching more holdings can only raise this share, never lower it.
73 holdings, 38 matched (32% of weight). Portfolio as of 2026-07-31, filed 2026-09-28. Source: SEC Form N-PORT.
8.06% of this portfolio’s income is non-permissible — weighted across holdings, computed over 29% of portfolio weight (33 of 73 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
Portfolio shares are withheld: coverage is below the floor needed to state one. The holdings themselves are below, because the names are evidence you can check.
All holdings (73)
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| GOLDMAN FINANCIAL | UNSCREENED | 22.36% | no in-house ratios for this holding |
| N/A | UNSCREENED | 16.36% | no in-house ratios for this holding |
| DREYFUS | UNSCREENED | 8.14% | no in-house ratios for this holding |
| N/A | UNSCREENED | 7.41% | no in-house ratios for this holding |
| CRINETICS PHARMACEUTICALS IN | UNSCREENED | 2.77% | no in-house ratios for this holding |
| MBX BIOSCIENCES INC | UNSCREENED | 2.42% | no in-house ratios for this holding |
| N/A | UNSCREENED | 2.28% | no in-house ratios for this holding |
| ATAI ATAIBECKLEY INC | NON_COMPLIANT | 2.16% | AAOIFI0.9% Usmani9.4% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic9.4% MSCI Islamic M-Series2.5% FTSE Shariah8.7% |
| Definium Therapeutics, Inc | UNSCREENED | 2.13% | no in-house ratios for this holding |
| GOLDMAN SACHS LIQ ES FD A | UNSCREENED | 2.03% | no in-house ratios for this holding |
| AMYLYX PHARMACEUTICALS INC | UNSCREENED | 1.72% | no in-house ratios for this holding |
| ENLIVEN THERAPEUTICS INC | UNSCREENED | 1.68% | no in-house ratios for this holding |
| CORT CORCEPT THERAPEUTICS INC | COMPLIANT | 1.67% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ALUMIS INC | UNSCREENED | 1.60% | no in-house ratios for this holding |
| NUVB NUVATION BIO INC | NON_COMPLIANT | 1.57% | AAOIFI10.5% Usmani33.9% Dow Jones Islamic18.7% S&P Shariah23.6% MSCI Islamic33.9% MSCI Islamic M-Series23.6% FTSE Shariah33.4% |
| TREVI THERAPEUTICS INC | UNSCREENED | 1.55% | no in-house ratios for this holding |
| LQDA LIQUIDIA CORP | COMPLIANT | 1.47% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| NKTR NEKTAR THERAPEUTICS | NON_COMPLIANT | 1.42% | AAOIFI3.1% Usmani7.2% Dow Jones Islamic8.2% S&P Shariah11.3% MSCI Islamic7.2% MSCI Islamic M-Series11.3% FTSE Shariah0.0% |
| AMNEAL PHARMACEUTICALS INC | UNSCREENED | 1.36% | no in-house ratios for this holding |
| BMY BRISTOL-MYERS SQUIBB CO | NON_COMPLIANT | 1.34% | AAOIFI37.3% Usmani51.1% Dow Jones Islamic42.2% S&P Shariah44.8% MSCI Islamic51.1% MSCI Islamic M-Series44.8% FTSE Shariah48.9% |
| EDGEWISE THERAPEUTICS INC | UNSCREENED | 1.33% | no in-house ratios for this holding |
| OMEROS CORP | UNSCREENED | 1.32% | no in-house ratios for this holding |
| LGND LIGAND PHARMACEUTICALS | COMPLIANT | 1.32% | AAOIFI19.7% Usmani51.8% Dow Jones Islamic34.1% S&P Shariah42.6% MSCI Islamic51.8% MSCI Islamic M-Series42.6% FTSE Shariah51.5% |
| ELAN ELANCO ANIMAL HEALTH INC | NON_COMPLIANT | 1.31% | AAOIFI31.2% Usmani27.5% Dow Jones Islamic41.7% S&P Shariah45.2% MSCI Islamic27.5% MSCI Islamic M-Series45.2% FTSE Shariah27.5% |
| VERADERMICS INC | UNSCREENED | 1.28% | no in-house ratios for this holding |
| PACIRA PHARMACEUTICALS INC | UNSCREENED | 1.28% | no in-house ratios for this holding |
| VTRS VIATRIS INC | NON_COMPLIANT | 1.27% | AAOIFI65.8% Usmani38.9% Dow Jones Islamic100.2% S&P Shariah105.1% MSCI Islamic38.9% MSCI Islamic M-Series105.1% FTSE Shariah38.1% |
| JAZZ JAZZ PHARMACEUTICALS PLC | COMPLIANT | 1.25% | AAOIFI38.6% Usmani46.9% Dow Jones Islamic55.2% S&P Shariah61.2% MSCI Islamic46.9% MSCI Islamic M-Series61.2% FTSE Shariah46.4% |
| ETON ETON PHARMACEUTICALS INC | COMPLIANT | 1.25% | AAOIFI1.7% Usmani25.2% Dow Jones Islamic5.4% S&P Shariah7.4% MSCI Islamic25.2% MSCI Islamic M-Series7.4% FTSE Shariah24.1% |
| MAZE MAZE THERAPEUTICS INC | COMPLIANT | 1.25% | AAOIFI4.2% Usmani11.4% Dow Jones Islamicfail S&P Shariahfail MSCI Islamic11.4% MSCI Islamic M-Seriesfail FTSE Shariah7.3% |
| MRK MERCK & COMPANY INC | COMPLIANT | 1.24% | AAOIFI14.7% Usmani41.5% Dow Jones Islamic21.8% S&P Shariah20.9% MSCI Islamic41.5% MSCI Islamic M-Series20.9% FTSE Shariah41.5% |
| CSM -N.R CERT | UNSCREENED | 1.23% | no in-house ratios for this holding |
| JNJ JOHNSON & JOHNSON | COMPLIANT | 1.22% | AAOIFI7.6% Usmani24.4% Dow Jones Islamic10.9% S&P Shariah11.7% MSCI Islamic24.4% MSCI Islamic M-Series11.7% FTSE Shariah24.4% |
| RPRX ROYALTY PHARMA PLC- CL A | NON_COMPLIANT | 1.22% | AAOIFI25.9% Usmani45.2% Dow Jones Islamic57.5% S&P Shariah64.9% MSCI Islamic45.2% MSCI Islamic M-Series64.9% FTSE Shariah45.2% |
| INDIVIOR PHARMACEUTICALS INC | UNSCREENED | 1.19% | no in-house ratios for this holding |
| PRESTIGE BRANDS HOLDINGS INC | UNSCREENED | 1.16% | no in-house ratios for this holding |
| COLL COLLEGIUM PHARMACEUTICAL INC | NON_COMPLIANT | 1.16% | AAOIFI31.8% Usmani11.4% Dow Jones Islamic21.9% S&P Shariah22.5% MSCI Islamic11.4% MSCI Islamic M-Series22.5% FTSE Shariah11.2% |
| OGN ORGANON & CO | NON_COMPLIANT | 1.15% | AAOIFI236.4% Usmani64.9% Dow Jones Islamic282.4% S&P Shariah250.1% MSCI Islamic64.9% MSCI Islamic M-Series250.1% FTSE Shariah64.9% |
| LLY ELI LILLY & COMPANY | COMPLIANT | 1.15% | AAOIFI5.2% Usmani38.6% Dow Jones Islamic6.4% S&P Shariah6.9% MSCI Islamic38.6% MSCI Islamic M-Series6.9% FTSE Shariah38.6% |
| EYPT EYEPOINT INC | NON_COMPLIANT | 1.13% | AAOIFIfail Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| HARMONY BIOSCIENCES HOLDINGS | UNSCREENED | 1.13% | no in-house ratios for this holding |
| SUPN SUPERNUS PHARMACEUTICALS INC | COMPLIANT | 1.13% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| PFE PFIZER INC | NON_COMPLIANT | 1.11% | AAOIFI39.8% Usmani31.4% Dow Jones Islamic46.1% S&P Shariah45.9% MSCI Islamic31.4% MSCI Islamic M-Series45.9% FTSE Shariah31.4% |
| WVE WAVE LIFE SCIENCES LTD | NON_COMPLIANT | 1.11% | AAOIFI3.9% Usmani7.8% Dow Jones Islamic2.9% S&P Shariah3.6% MSCI Islamic7.8% MSCI Islamic M-Series3.6% FTSE Shariah0.0% |
| PAHC PHIBRO ANIMAL HEALTH CORP-A | NON_COMPLIANT | 1.11% | AAOIFI43.6% Usmani45.1% Dow Jones Islamic51.7% S&P Shariah64.2% MSCI Islamic45.1% MSCI Islamic M-Series64.2% FTSE Shariah41.3% |
| ANIP ANI PHARMACEUTICALS INC | NON_COMPLIANT | 1.10% | AAOIFI18.1% Usmani20.2% Dow Jones Islamic16.7% S&P Shariah17.8% MSCI Islamic20.2% MSCI Islamic M-Series17.8% FTSE Shariah20.2% |
| TARS TARSUS PHARMACEUTICALS INC | COMPLIANT | 1.10% | AAOIFI2.3% Usmani14.5% Dow Jones Islamic3.8% S&P Shariah4.7% MSCI Islamic14.5% MSCI Islamic M-Series4.7% FTSE Shariah11.9% |
| ZTS ZOETIS INC | NON_COMPLIANT | 1.08% | AAOIFI29.0% Usmani61.3% Dow Jones Islamic15.4% S&P Shariah14.0% MSCI Islamic61.3% MSCI Islamic M-Series14.0% FTSE Shariah60.0% |
| OCUL OCULAR THERAPEUTIX INC | NON_COMPLIANT | 1.06% | AAOIFI0.3% Usmani1.0% Dow Jones Islamic0.4% S&P Shariah0.5% MSCI Islamic1.0% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| XERS XERIS BIOPHARMA HOLDINGS INC | COMPLIANT | 1.06% | AAOIFI19.9% Usmani70.3% Dow Jones Islamic30.4% S&P Shariah39.2% MSCI Islamic70.3% MSCI Islamic M-Series39.2% FTSE Shariah61.3% |
| RAPPORT THERAPEUTICS INC | UNSCREENED | 1.05% | no in-house ratios for this holding |
| INVA INNOVIVA INC | NON_COMPLIANT | 1.04% | AAOIFI17.5% Usmani15.8% Dow Jones Islamic19.8% S&P Shariah21.9% MSCI Islamic15.8% MSCI Islamic M-Series21.9% FTSE Shariah15.2% |
| PRGO PERRIGO CO PLC | NON_COMPLIANT | 1.03% | AAOIFI167.1% Usmani45.6% Dow Jones Islamic136.7% S&P Shariah120.3% MSCI Islamic45.5% MSCI Islamic M-Series120.3% FTSE Shariah43.3% |
| AXSM AXSOME THERAPEUTICS INC | COMPLIANT | 1.01% | AAOIFI1.9% Usmani29.5% Dow Jones Islamic2.9% S&P Shariah3.5% MSCI Islamic27.6% MSCI Islamic M-Series3.5% FTSE Shariah24.7% |
| AMPHASTAR PHARMACEUTICALS IN | UNSCREENED | 0.92% | no in-house ratios for this holding |
| ARVINAS INC | UNSCREENED | 0.90% | no in-house ratios for this holding |
| ALTO NEUROSCIENCE INC | UNSCREENED | 0.90% | no in-house ratios for this holding |
| SEPN SEPTERNA INC | NON_COMPLIANT | 0.76% | AAOIFI1.3% Usmani4.0% Dow Jones Islamic2.4% S&P Shariahfail MSCI Islamic4.0% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| LB PHARMACEUTICALS INC | UNSCREENED | 0.73% | no in-house ratios for this holding |
| CORMEDIX INC | UNSCREENED | 0.72% | no in-house ratios for this holding |
| THERAVANCE BIOPHARMA INC | UNSCREENED | 0.71% | no in-house ratios for this holding |
| ACRS ACLARIS THERAPEUTICS INC | NON_COMPLIANT | 0.65% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| PHAT PHATHOM PHARMACEUTICALS INC | NON_COMPLIANT | 0.64% | AAOIFI55.2% Usmani123.6% Dow Jones Islamic53.0% S&P Shariah57.8% MSCI Islamic123.6% MSCI Islamic M-Series57.8% FTSE Shariah122.8% |
| ZEVRA THERAPEUTICS INC | UNSCREENED | 0.61% | no in-house ratios for this holding |
| RLMD RELMADA THERAPEUTICS INC | NON_COMPLIANT | 0.61% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| N/A | UNSCREENED | 0.60% | no in-house ratios for this holding |
| AQST AQUESTIVE THERAPEUTICS INC | COMPLIANT | 0.51% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| FULCRUM THERAPEUTICS INC | UNSCREENED | 0.50% | no in-house ratios for this holding |
| LEXICON GENETICS INCORPORATED | UNSCREENED | 0.45% | no in-house ratios for this holding |
| BIOA BIOAGE LABS INC | NON_COMPLIANT | 0.41% | AAOIFI0.6% Usmani0.7% Dow Jones Islamic0.6% S&P Shariah— MSCI Islamic0.7% MSCI Islamic M-Series— FTSE Shariah0.0% |
| EOLS EVOLUS INC | NON_COMPLIANT | 0.33% | AAOIFI33.9% Usmani66.4% Dow Jones Islamic30.4% S&P Shariah26.7% MSCI Islamic66.4% MSCI Islamic M-Series26.7% FTSE Shariah63.2% |
| MALLINCKRODT PLC | UNSCREENED | 0.00% | no in-house ratios for this holding |
| ESPERION THERAPEUTICS INC | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 9 points of portfolio weight — 13.8% of it passes AAOIFI, 4.8% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 13.8% ratios fail on 23.6% 96.8% not rated under AAOIFI
ratios pass on 7.1% ratios fail on 28.3% 98.7% not rated under Usmani
ratios pass on 12.8% ratios fail on 22.2% 99.2% not rated under Dow Jones Islamic
ratios pass on 11.7% ratios fail on 22.9% 99.6% not rated under S&P Shariah
ratios pass on 4.8% ratios fail on 29.6% 99.8% not rated under MSCI Islamic
ratios pass on 11.7% ratios fail on 22.9% 99.6% not rated under MSCI Islamic M-Series
ratios pass on 7.1% ratios fail on 28.3% 98.7% not rated under FTSE Shariah
38 of 73 listed holdings carry our own per-methodology verdicts (42% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 33 (37% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| ATAI ATAIBECKLEY INC | 2.16% |
| NUVB NUVATION BIO INC | 1.57% |
| NKTR NEKTAR THERAPEUTICS | 1.42% |
| BMY BRISTOL-MYERS SQUIBB CO | 1.34% |
| ELAN ELANCO ANIMAL HEALTH INC | 1.31% |
| VTRS VIATRIS INC | 1.27% |
| RPRX ROYALTY PHARMA PLC- CL A | 1.22% |
| COLL COLLEGIUM PHARMACEUTICAL INC | 1.16% |
| OGN ORGANON & CO | 1.15% |
| EYPT EYEPOINT INC | 1.13% |
Methodology breakdown computing — it will appear here on its own.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for PILL — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 49.80 | NEUTRAL |
| Stochastic %K (14) | 60.98 | NEUTRAL |
| CCI (20) | 22.33 | NEUTRAL |
| Williams %R (14) | -39.02 | NEUTRAL |
| MACD (12,26,9) | 0.18 | BUY |
| ROC (10) | 9.21 | BUY |
| Momentum (10) | 1.28 | BUY |
| EMA (10) | 14.83 | BUY |
| SMA (10) | 14.87 | BUY |
| EMA (20) | 14.96 | BUY |
| SMA (20) | 14.57 | BUY |
| EMA (30) | 15.33 | SELL |
| SMA (30) | 14.82 | BUY |
| EMA (50) | 16.03 | SELL |
| SMA (50) | 16.45 | SELL |
| EMA (100) | 16.34 | SELL |
| SMA (100) | 17.95 | SELL |
| EMA (200) | 14.68 | BUY |
| SMA (200) | 14.93 | BUY |
About Direxion Daily Pharmaceutical & Medical Bull 3X Shares
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks, defined as pharmaceutical and medical stocks, comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 43 |
| ⏰ 4H | BULLISH | 18 |
| 🕐 1H | BEARISH | 74 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is a fund screened on its name?
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
What does unrated weight mean?
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
Does the issuer's board make it compliant?
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
How often is this re-screened?
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-03 · Asset managers net 928584 (+5135)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.